BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 26773572)

  • 1. Treatment of muscle-invasive bladder cancer: A systematic review.
    Chou R; Selph SS; Buckley DI; Gustafson KS; Griffin JC; Grusing SE; Gore JL
    Cancer; 2016 Mar; 122(6):842-51. PubMed ID: 26773572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
    Milowsky MI; Stadler WM; Bajorin DF
    BJU Int; 2008 Nov; 102(9 Pt B):1339-44. PubMed ID: 19035902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of node dissection in relation to neoadjuvant and adjuvant therapy.
    Huang WC; Bochner BH
    J Natl Compr Canc Netw; 2006 Nov; 4(10):1019-26. PubMed ID: 17112450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current controversies on the role of lymphadenectomy for bladder cancer.
    Ghodoussipour S; Daneshmand S
    Urol Oncol; 2019 Mar; 37(3):193-200. PubMed ID: 29909945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
    Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
    Eur Urol; 2011 Jun; 59(6):1009-18. PubMed ID: 21454009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the treatment of bladder cancer.
    Kaufman DS
    Ann Oncol; 2006 May; 17 Suppl 5():v106-12. PubMed ID: 16807436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
    Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
    Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
    Izawa JI; Chin JL; Winquist E
    Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy.
    Feifer AH; Taylor JM; Tarin TV; Herr HW
    Eur Urol; 2011 Jun; 59(6):978-84. PubMed ID: 21257257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy.
    Yuh B; Wilson T; Bochner B; Chan K; Palou J; Stenzl A; Montorsi F; Thalmann G; Guru K; Catto JW; Wiklund PN; Novara G
    Eur Urol; 2015 Mar; 67(3):402-22. PubMed ID: 25560797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landmarks in the treatment of muscle-invasive bladder cancer.
    Lobo N; Mount C; Omar K; Nair R; Thurairaja R; Khan MS
    Nat Rev Urol; 2017 Sep; 14(9):565-574. PubMed ID: 28675174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
    World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder-sparing treatment of invasive bladder cancer.
    Rivera I; Wajsman Z
    Cancer Control; 2000; 7(4):340-6. PubMed ID: 10895128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
    Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
    Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical factors influence bladder cancer outcomes: a cooperative group report.
    Herr HW; Faulkner JR; Grossman HB; Natale RB; deVere White R; Sarosdy MF; Crawford ED
    J Clin Oncol; 2004 Jul; 22(14):2781-9. PubMed ID: 15199091
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.